PMV Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
The meeting featured the election of two directors, approval of executive compensation, and auditor ratification. No shareholder questions were raised, and all proposals passed as recommended by the board.
-
Rezatapopt demonstrates strong efficacy and safety in heavily pretreated ovarian cancer, with a 46% ORR and 8-month median DOR. NDA submission is planned for Q1 2027, with global expansion and combination studies underway. US market potential is estimated at $350–$420 million.
Fiscal Year 2025
-
The company is advancing Rezatapopt, targeting the TP53 Y220C mutation, through a phase II basket study with ovarian cancer as the anchor. Interim data from 50 patients is expected mid-2025, with NDA submission planned for late 2026. Cash reserves support operations through this period.
-
The pivotal phase II trial is on track, with interim data for 50 patients expected in July-August, focusing on ovarian and other solid tumors with Y220C p53 mutations. Regulatory and commercial strategies are flexible, with strong financials and ongoing combination studies in AML-MDS.
-
Rezatapopt, a first-in-class p53 reactivator, is in a pivotal Phase II trial for TP53 Y220C mutant solid tumors, with interim analysis mid-2024 and NDA submission targeted for end of 2026. The program shows promising efficacy and safety, with global expansion and new pipeline candidates underway.
-
Rezatapopt's Phase 2 trial targets multiple solid tumors, with a focus on ovarian cancer and a tumor-agnostic strategy. Interim data will be released mid-2024, supporting an NDA submission by end of 2026. Pipeline expansion and combination studies are ongoing.